Tsvi Segal, MD; Ana Schwartz, MD; Konstantin Konfino, MD, PhD
Objective: In this post marketing study our primary objective was to assess the safety of Crystalys, a new calcium hydroxyapatite based filler, in subjects who received sub-dermal or deep-dermal injections for facial soft tissue augmentation. The secondary objective was to evaluate the performance of Crystalys within six months of injection.
Methods: Crystalys was injected to 173 patients, age ranging from 27–72 years, with a variety of facial aesthetic conditions, most common being pronounced nasolabial folds. On average, patients were injected with 3.4 ml of Crystalys. After obtaining informed consent
form, the subjects were evaluated for adverse events (AEs) and efficacy using three different performance methods.
